Download
s12893-021-01083-9.pdf 839,11KB
WeightNameValue
1000 Titel
  • Effect of platelet inhibition with perioperative aspirin on survival in patients undergoing curative resection for pancreatic cancer: a propensity score matched analysis
1000 Autor/in
  1. Pretzsch, E. |
  2. D’Haese, J. G. |
  3. Renz, B. |
  4. Ilmer, M. |
  5. Schiergens, T. |
  6. Miksch, R. C. |
  7. Albertsmeier, M. |
  8. Guba, M. |
  9. Angele, M. K. |
  10. Werner, J. |
  11. Nieß, H. |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-02-22
1000 Erschienen in
1000 Quellenangabe
  • 21(1):98
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1186/s12893-021-01083-9 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7901208/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Background!#!The importance of platelets in the pathogenesis of metastasis formation is increasingly recognized. Although evidence from epidemiologic studies suggests positive effects of aspirin on metastasis formation, there is little clinical data on the perioperative use of this drug in pancreatic cancer patients.!##!Methods!#!From all patients who received curative intent surgery for pancreatic cancer between 2014 and 2016 at our institution, we identified 18 patients that took aspirin at time of admission and continued to throughout the inpatient period. Using propensity score matching, we selected a control group of 64 patients without aspirin intake from our database and assessed the effect of aspirin medication on overall, disease-free, and hematogenous metastasis-free survival intervals as endpoints.!##!Results!#!Aspirin intake proved to be independently associated with improved mean overall survival (OS) (46.5 vs. 24.6 months, *p = 0.006), median disease-free survival (DFS) (26 vs. 10.5 months, *p = 0.001) and mean hematogenous metastasis-free survival (HMFS) (41.9 vs. 16.3 months, *p = 0.005). Three-year survival rates were 61.1% in patients with aspirin intake vs. 26.3% in patients without aspirin intake. Multivariate cox regression showed significant independent association of aspirin with all three survival endpoints with hazard ratios of 0.36 (95% CI 0.15-0.86) for OS (*p = 0.021), 0.32 (95% CI 0.16-0.63) for DFS (**p = 0.001), and 0.36 (95% CI 0.16-0.77) for HMFS (*p = 0.009).!##!Conclusions!#!Patients in our retrospective, propensity-score matched study showed significantly better overall survival when taking aspirin while undergoing curative surgery for pancreatic cancer. This was mainly due to a prolonged metastasis-free interval following surgery.
1000 Sacherschließung
lokal Adjuvant aspirin
lokal Perioperative Care [MeSH]
lokal Pancreatic surgery
lokal Humans [MeSH]
lokal Treatment Outcome [MeSH]
lokal Retrospective Studies [MeSH]
lokal Visceral and general surgery
lokal Platelet Aggregation Inhibitors/therapeutic use [MeSH]
lokal Micrometastasis
lokal Survival Rate [MeSH]
lokal Actylsalicylic acid
lokal Circulating tumor cells
lokal Aspirin/therapeutic use [MeSH]
lokal Propensity Score [MeSH]
lokal Pancreatic Neoplasms/surgery [MeSH]
lokal Research Article
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/UHJldHpzY2gsIEUu|https://frl.publisso.de/adhoc/uri/ROKAmUhhZXNlLCBKLiBHLg==|https://frl.publisso.de/adhoc/uri/UmVueiwgQi4=|https://frl.publisso.de/adhoc/uri/SWxtZXIsIE0u|https://frl.publisso.de/adhoc/uri/U2NoaWVyZ2VucywgVC4=|https://frl.publisso.de/adhoc/uri/TWlrc2NoLCBSLiBDLg==|https://frl.publisso.de/adhoc/uri/QWxiZXJ0c21laWVyLCBNLg==|https://frl.publisso.de/adhoc/uri/R3ViYSwgTS4=|https://frl.publisso.de/adhoc/uri/QW5nZWxlLCBNLiBLLg==|https://frl.publisso.de/adhoc/uri/V2VybmVyLCBKLg==|https://frl.publisso.de/adhoc/uri/Tmllw58sIEgu
1000 Hinweis
  • DeepGreen-ID: 0adbd09c5720485d9653dc11e609adf2 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6465353.rdf
1000 Erstellt am 2023-11-16T13:11:15.866+0100
1000 Erstellt von 322
1000 beschreibt frl:6465353
1000 Zuletzt bearbeitet Fri Dec 01 02:06:02 CET 2023
1000 Objekt bearb. Fri Dec 01 02:06:02 CET 2023
1000 Vgl. frl:6465353
1000 Oai Id
  1. oai:frl.publisso.de:frl:6465353 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source